References
- Saven A., Piro L.D. Newer purine analogues for the treatment of hairy cell leukemia. N. Engl. J. Med. 1994; 330: 691–697
- Pott-Hoeck C., Hiddeman W. Purine analogs in the treatment of low-grade lymphomas and lymphocytic leukemias. Ann. Oncol. 1995; 6: 421–433
- Juliusson G., Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol. 1993; 11: 679–689
- Robak T., Gora-Tybor J., Krykowski E., Walewski J.A., Borawska A., Pluzanska A., Potemski P., Hellmann A., Zaucha J.M., Konopka L., Ceglarek B., Durzynski T., Sikorska A., Michalak K., Urasinski J., Opalinska J., Dmoszynska A., Adamczyk-Cioch M.D., Kuratowska Z., Dwilewicz J., Bogurodzki P., Deren M., Grieb P. Activity of 2-chlorodeoxyadenosine in 94 previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk. Lymph. 1997; 26: 99–105
- Robak T., Blasinska-Morawiec M., Krykowski E., Hansz J., Komarnicki M., Kazimierczak M., Konopka L., Maj S., Hellmann A., Zaucha J.M., Urasinski J., Zdziarska B., Kotlarek-Haus S., Usnarska-Zubkiewicz L., Kuratowska Z., Dwilewicz-Trojaczek J., Holowiecki J., Krawczyk-Kulis M., Grieb P. 2-Chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk. Lymph. 1996; 22: 107–111
- Szmigielska A., Gora-Tybor J., Robak T. Influence of 2-chlorodeoxyadenosine alone and in combination with cytosine arabinoside on murine leukemias L1210 and P388. Cancer J. 1996; 9: 319–322
- Telfieri A., Witzig T.E., Reid J.M., Li C-Y., Amos M.M. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J. Clin. Oncol. 1994; 12: 569–574
- Begleiter A, Wang H., Verburg L., Lee K., Israels L.G., Mowat M.R.A., Johnston J.B. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Leukemia 1959; 10, 1965
- Robak T., Korycka A. The comparison of 2-chlorodeoxyadenosine (2-CdA) in combination with interferon α (IFNα) or interferon γ (IFNγ) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts (CFU-L) in in vitro cultures. Leuk. Lymph. 1996; 21: 161–168
- Gora-Tybor J., Robak T. Does interleukin-2 enhance the antitumor activity of 2-chlorodeoxyadenosine? Cancer J. 1997; 10: 171–174
- Robak T., Blasinska-Morawiec M., Blonski J.Z., Krykowski E., Komarnicki M., Trepinska E., Kazmierczak M., Hansz J., Dmoszynska A., Rolinski J., Konopka L., Skotnicki A.B., Nowak W.S., Kotlarek-Haus S, Zdziarska B., Urasinski J. The effect of 2-hour infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia. Eur. J. Cancer 1997; 33: 2347–2351
- Mc Laughlin P., Hagemeister F.B., Romaguera J.E., Sarris A.H., Pate O., Younes A., Swan F., Keating M., Cabanillas F. Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma. J. Clin. Oncol. 1996; 14: 1262–1268
- Saven A., Lee T., Kosty M., Piro L.D. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 1996; 14: 2139–2144
- Stansfeld A.G., Diebold J., Kapanci Y., Kelenyi G., Lennert K., Mioduszewska O., Noel H., Rilke F., Sundstrom C., van Unnik J.A.M., Wright D.H. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292–293
- Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., Mc Fadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5: 649–655
- Faulds D., Balfour J.A., Chrisp P., Langtry H.D. Mitoxantrone: A review of its pharmacodynamic and phar-macokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 41: 400–449
- Liliemark J., Porwit A., Juliusson G. Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk. Lymph. 1997; 25: 313–318